

November 15, 2013

Evonik positions itself in oncology

Essen. Evonik Industries has launched a new website aimed specifically at manufacturers of oncology drugs. The new site, www.evonik.com/oncology-drugs, provides pharmaceutical companies with an overview of Evonik's competencies in this space. They include a proven track record in production of high-potency actives, development of drug delivery systems, generation of clinical samples, and commercial-scale manufacture of parenteral oncology drug products.

"The development and manufacturing of effective cancer drugs present significant challenges. Evonik with its broad competencies can help pharmaceutical companies overcome these hurdles and accelerate the development process." said Dr. Jean-Luc Herbeaux, the head of the Health Care Business Line of Evonik.

The new website describes the company's Hanau, Germany, and Tippecanoe, U.S., sites' capacities to produce highly potent active pharmaceutical ingredients (HPAPIs) in any volume from laboratory to commercial scale.

It also describes the pharmaceutical polymer platforms of Evonik, EUDRAGIT® and RESOMER®, which afford options to manufacture intelligent drug delivery systems for oral and parenteral administration. Thanks to their targeted and controlled release, these polymers contribute to reducing the dosage and cancer therapy length for the patient's benefit.

Evonik is also able to support pharmaceutical companies with formulation development. To give an example, Evonik has expertise in spray drying and melt extrusion, which can overcome the bioavailability problems that frequently occur with HPAPIs.

The company's certified facilities in Darmstadt, Germany and Birmingham, U.S. allow for the production of clinical samples for

Contact person specialized press
Dr. Jürgen Krauter
Communication, Health & Nutrition
Phone +49 6181 59-6847
Fax +49 6181 59-76847
Juergen.krauter@evonik.com

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.de

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Thomas Haerberle,
Thomas Wessel, Patrik Wohlhauser,
Ute Wolf, Dr. Dahai Yu

Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

phase II (oral) and III (parenteral) trials. The Birmingham site is also equipped to produce a broad spectrum of complex parenteral drug systems for cancer therapies, such as micro-size and nanoparticles, liposomes, or lyophilisates.

"Thanks to our global presence, competencies in many areas of drug development, unique technologies and ultra-high quality standards, we are well positioned to support our pharmaceutical customers in their development projects," notes Herbeaux.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.